Introduction: Finding products that control viral replication directly or indirectly on SARS-CoV-2 infection remains a challenge. Potassium Ribosate (RK), which has been shown to have an enhancer effect in limiting replication and viability in cancer cells, also appears promising for altering viral replication. Methods: To determine its activity against SARS-CoV-2, an inhibition test was performed using 26 strains obtained from clinical samples of patients isolated on the Vero E6 cell line. For this, the strains were diluted in series and treated with 125mM of RK. Ribosate was administered in a single concentration (125 mM stock) in two ways: 24 hours before infection and in the culture medium after removal of the infectious inoculum. The culture medium was changed 3 days after inoculation. Seven days after inoculation, a visual reading of the cytopathic effect (CPE) and RT-qRCP was performed to calculate the viral load. The reduction of 3log (9Ct) between control and the Treaty was considered a very good response. Results: Of the 26 evaluable strains, a reduction in viral replication was observed in 13 (50%) and 16 (61.5%) of the pretreatment and treatment study (p=0.29). This response was good or very good in 10 (38.4%) and 11 (42.3%) (p=0.4), respectively. Conclusion: RK administration reduced the viral load of SARS-CoV-2 cultures in Vero E6 cells in more than half of the cases tested.